Related Experiment Video
Updated: Jun 8, 2026
Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
[Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the
1Servicio de Microbiología, Consorcio Hospital General Universitario y Facultad de Medicina, Universidad de Valencia, Spain. Concepcion.Gimeno@uv.es
Introduction:
Doripenem is a new carbapenem with broad spectrum antibacterial activity indicated for the treatment of nosocomial pneumonia and complicated urinary and intraabdominal infections.
Methods:
Isolates of Pseudomonas aeruginosa, Acinetobacter and Enterobacteriaceae from patients with nosocomial pneumonia, bacteremia and complicated intraabdominal infections attended in 16 Spanish hospitals were included (October 2008-May 2009). Susceptibility to imipenem, meropenem and doripenem was studied with the Etest method, and the results were interpreted according to the EUCAST criteria.
Results:
Considering all the isolates, doripenem (MIC(50) 0.12 mg/L) was 2- to 8-fold more active than meropenem (0.25 mg/L) and imipenem (1 mg/L). In relation to Enterobacteriaceae, the MIC(50) and MIC(90) values of doripenem and meropenem were similar (0.03 and 0.12 mg/L, respectively) and clearly superior to those of imipenem (0.25 and 1 mg/L). In the case of P. aeruginosa, MIC(50) and MIC(90) were more favorable to doripenem (0.25 and 16 mg/L) than to meropenem (0.5 and ≥64 mg/L) or imipenem (2 and ≥64 mg/L). In this species, the percentage of strains with lower MIC values for doripenem among those exhibiting intermediate susceptibility and resistance to meropenem was 63.0% (29/46) and 61.7% (63/102), respectively, versus only 4.3% (2/46) and 1.9% (2/102) with higher MIC values for doripenem.
Conclusions:
The results obtained in this study are similar to those reported in other countries, and reinforce the superior in vitro activity of doripenem versus the other carbapenems and its position in the treatment guidelines regarding the nosocomial infections for which it is indicated.
Insights
Doripenem demonstrates superior in vitro activity against nosocomial pathogens compared to meropenem and imipenem. This carbapenem antibiotic is a strong option for treating serious bacterial infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Doripenem is a novel carbapenem antibiotic.
- It exhibits broad-spectrum antibacterial activity.
- Indicated for nosocomial pneumonia and complicated infections.
Purpose of the Study:
- To evaluate the in vitro activity of doripenem.
- Compare doripenem to meropenem and imipenem.
- Assess efficacy against key nosocomial pathogens.
Main Methods:
- Collected bacterial isolates from 16 Spanish hospitals (Oct 2008-May 2009).
- Included Pseudomonas aeruginosa, Acinetobacter, and Enterobacteriaceae.
- Determined susceptibility using Etest and EUCAST criteria.
Main Results:
- Doripenem showed 2- to 8-fold greater activity than meropenem and imipenem.
- Doripenem and meropenem were similar against Enterobacteriaceae, superior to imipenem.
- Doripenem exhibited more favorable MIC values against P. aeruginosa than meropenem or imipenem.
Conclusions:
- Doripenem's in vitro activity is superior to other carbapenems.
- Results align with international findings.
- Supports doripenem's role in treating indicated nosocomial infections.
Related Concept Videos
01:28Antimicrobial Effectiveness
01:25Clinical Significance of Antibiotic Resistance
00:57Antibiotic Selection
01:30Development of Antibiotic Resistance
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:25Mechanism of Antibiotic Resistance in MRSA